A cell-based high-throughput screening assay for radiation susceptibility using automated cell counting

Radiation Oncology

Victor W van Beusechem⁴  Baukelien van Triest³  Albert A Geldof⁶  Winald R Gerritsen⁵  Marcel Verheij³  Stan Heukelom¹  Renee X de Menezes²  Ida H van der Meulen-Muileman⁴  Mariëlle JP Maas⁴  Ilse Dingjan⁴  Jasmina Hodzic⁴ 

[1] Department of Radiology & Nuclear Medicine, VU University Medical Center, De Boelelaan 1118, Amsterdam, 1081HV, The Netherlands;Department of Epidemiology and Biostatistics, VU University Medical Center, De Boelelaan 1118, Amsterdam, 1081HV, The Netherlands;Department of Radiotherapy, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, The Netherlands;Department of Medical Oncology, VU University Medical Center, De Boelelaan 1118, Amsterdam, 1081HV, The Netherlands;Present address: Department of Medical Oncology, The Radboud University Medical Center, Comeniuslaan 4, Nijmegen, 6525 HP, The Netherlands;Department of Urology, VU University Medical Center, De Boelelaan 1118, Amsterdam, 1081HV, The Netherlands

关键词: Assay development;    Microplate laser scanning;    High-throughput screening;    Radiosensitization;   

Others  :  1139714
DOI  :  10.1186/s13014-015-0355-2

 received in 2014-08-11, accepted in 2015-02-13,  发布年份 2015

【 摘 要 】

Background

Radiotherapy is one of the mainstays in the treatment for cancer, but its success can be limited due to inherent or acquired resistance. Mechanisms underlying radioresistance in various cancers are poorly understood and available radiosensitizers have shown only modest clinical benefit. There is thus a need to identify new targets and drugs for more effective sensitization of cancer cells to irradiation. Compound and RNA interference high-throughput screening technologies allow comprehensive enterprises to identify new agents and targets for radiosensitization. However, the gold standard assay to investigate radiosensitivity of cancer cells in vitro, the colony formation assay (CFA), is unsuitable for high-throughput screening.

Methods

We developed a new high-throughput screening method for determining radiation susceptibility. Fast and uniform irradiation of batches up to 30 microplates was achieved using a Perspex container and a clinically employed linear accelerator. The readout was done by automated counting of fluorescently stained nuclei using the Acumen eX3 laser scanning cytometer. Assay performance was compared to that of the CFA and the CellTiter-Blue homogeneous uniform-well cell viability assay. The assay was validated in a whole-genome siRNA library screening setting using PC-3 prostate cancer cells.

Results

On 4 different cancer cell lines, the automated cell counting assay produced radiation dose response curves that followed a linear-quadratic equation and that exhibited a better correlation to the results of the CFA than did the cell viability assay. Moreover, the cell counting assay could be used to detect radiosensitization by silencing DNA-PKcs or by adding caffeine. In a high-throughput screening setting, using 4 Gy irradiated and control PC-3 cells, the effects of DNA-PKcs siRNA and non-targeting control siRNA could be clearly discriminated.

Conclusions

We developed a simple assay for radiation susceptibility that can be used for high-throughput screening. This will aid the identification of molecular targets for radiosensitization, thereby contributing to improving the efficacy of radiotherapy.

【 授权许可】

   
2015 Hodzic et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Auperin A, Le Pechoux C, Rolland E, Curran WJ, Furuse K, Fournel P et al.. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010; 28:2181-90.
• [2]Begg AC, Stewart FA, Vens C. Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer. 2011; 11:239-53.
• [3]Green JA, Kirwan JM, Tierney JF, Symonds P, Fresco L, Collingwood M et al.. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet. 2001; 358:781-6.
• [4]Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C et al.. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012; 30:1926-33.
• [5]Hoppe R, Phillips T, Roach M. Textbook of radiation oncology. 3rd ed. Elsevier Health Sciences, Philadelphia; 2010.
• [6]Bentzen SM, Overgaard J. Clinical normal-tissue radiobiology. In: Current radiation oncology. Tobias JS, Thomas PRM, editors. Arnold, London; 1996: p.37-67.
• [7]Taiakina D, Pra AD, Bristow RG. Intratumoral hypoxia as the genesis of genetic instability and clinical prognosis in prostate cancer. Adv Exp Med Biol. 2014; 772:189-204.
• [8]Lobrich M, Jeggo PA. The impact of a negligent G2/M checkpoint on genomic instability and cancer induction. Nat Rev Cancer. 2007; 7:861-9.
• [9]Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P et al.. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol. 2005; 77:18-24.
• [10]Kastan MB. DNA damage responses: mechanisms and roles in human disease: 2007 G.H.A. Clowes Memorial Award Lecture. Mol Cancer Res. 2008; 6:517-24.
• [11]Verheij M, Vens C, van Triest B. Novel therapeutics in combination with radiotherapy to improve cancer treatment: rationale, mechanisms of action and clinical perspective. Drug Resist Updat. 2010; 13:29-43.
• [12]Katz D, Ito E, Liu FF. On the path to seeking novel radiosensitizers. Int J Radiat Oncol Biol Phys. 2009; 73:988-96.
• [13]Ghotra VP, Geldof AA, Danen EH. Targeted radiosensitization in prostate cancer. Curr Pharm Des. 2013; 19:2819-28.
• [14]Albert JM, Cao C, Kim KW, Willey CD, Geng L, Xiao D et al.. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res. 2007; 13:3033-42.
• [15]Sarkaria JN, Busby EC, Tibbetts RS, Roos P, Taya Y, Karnitz LM et al.. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res. 1999; 59(17):4375-82.
• [16]Moding EJ, Kastan MB, Kirsch DG. Strategies for optimizing the response of cancer and normal tissues to radiation. Nat Rev Drug Discov. 2013; 12:526-42.
• [17]Overgaard J. Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck–a systematic review and meta-analysis. Radiother Oncol. 2011; 100:22-32.
• [18]Bartelink H, Roelofsen F, Eschwege F, Rougier P, Bosset JF, Gonzalez DG et al.. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol. 1997; 15:2040-9.
• [19]Bartelink H, Schellens JH, Verheij M. The combined use of radiotherapy and chemotherapy in the treatment of solid tumours. Eur J Cancer. 2002; 38:216-22.
• [20]Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al.. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352:987-96.
• [21]van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP et al.. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012; 366:2074-84.
• [22]Blockhuys S, Vanhoecke B, Smet J, De PB, Van CR, Bracke M et al.. Unraveling the mechanisms behind the enhanced MTT conversion by irradiated breast cancer cells. Radiat Res. 2013; 179:433-43.
• [23]Blockhuys S, Vanhoecke B, Paelinck L, Bracke M, De Wagter C. Development of in vitro models for investigating spatially fractionated irradiation: physics and biological results. Phys Med Biol. 2009; 54:1565-78.
• [24]Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for Use in evaluation and validation of high throughput screening assays. J Biomol Screen. 1999; 4:67-73.
• [25]Birmingham A, Selfors LM, Forster T, Wrobel D, Kennedy CJ, Shanks E et al.. Statistical methods for analysis of high-throughput RNA interference screens. Nat Methods. 2009; 6:569-75.
• [26]Cahill DP, da Costa LT, Carson-Walter EB, Kinzler KW, Vogelstein B, Lengauer C. Characterization of MAD2B and other mitotic spindle checkpoint genes. Genomics. 1999; 58:181-7.
• [27]Cheung HW, Chun AC, Wang Q, Deng W, Hu L, Guan XY et al.. Inactivation of human MAD2B in nasopharyngeal carcinoma cells leads to chemosensitization to DNA-damaging agents. Cancer Res. 2006; 66:4357-67.
• [28]Ni XH, Zhang YG, Ribas J, Chowdhury WH, Castanares M, Zhang ZW et al.. Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts. J Clin Invest. 2011; 121:2383-90.